Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AFA-P30
- Development stage
- Unknown
- Lead developer
- AfaSci
- Modality
- Peptides
01
Overview
AFA-P30 is a synthetic peptide drug candidate developed by AfaSci for the treatment of pain, particularly in the context of nervous system diseases. Its mechanism of action involves modulation of the calcitonin gene-related peptide (CGRP) pathway, which is implicated in pain signaling and migraine pathophysiology. As a CGRP modulator, it aims to alter CGRP activity to provide analgesic effects. The drug is currently at the discovery stage and has not yet entered clinical trials or received regulatory approval[6].
- Other names
- AFA-P30AFA-P-30AFA-P 30AFA P30AFAP30AFAP-30AFAP 30
02
Targets
Calcitonin gene-related peptide type 1 receptor
Beyond the preview
Go deeper on AFA-P30.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AFA-P30.